FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093666912> ?p ?o ?g. }

• W2093666912 endingPage "403" @default.
• W2093666912 startingPage "394" @default.
• W2093666912 abstract "Summary. This phase 3, randomized, double‐blind, placebo‐controlled study was designed to evaluate the efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Patients ( n = 344) with lymphoma or myeloma received darbepoetin alfa 2·25 μg/kg or placebo s.c., once weekly for 12 weeks. The percentage of patients achieving a haemoglobin response was significantly higher in the darbepoetin alfa group (60%) than in the placebo group (18%) ( P < 0·001), regardless of baseline endogenous erythropoietin level. However, increased responsiveness was observed in patients with lower baseline erythropoietin levels. Darbepoetin alfa also resulted in higher mean changes in haemoglobin than placebo from baseline to the last value during the treatment phase (1·80 g/dl vs 0·19 g/dl) and after 12 weeks of treatment (2·66 g/dl vs 0·69 g/dl). A significantly lower percentage of patients in the darbepoetin alfa group received red blood cell transfusions than in the placebo group ( P < 0·001). The efficacy of darbepoetin alfa was consistent for patients with lymphoma or myeloma. Improvements in quality of life were also observed with darbepoetin alfa. The overall safety profile of darbepoetin alfa was consistent with that expected for this patient population. Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy." @default.
• W2093666912 created "2016-06-24" @default.
• W2093666912 creator A5016338515 @default.
• W2093666912 creator A5017763871 @default.
• W2093666912 creator A5020989412 @default.
• W2093666912 creator A5028760009 @default.
• W2093666912 creator A5032502229 @default.
• W2093666912 creator A5033539146 @default.
• W2093666912 creator A5043378112 @default.
• W2093666912 creator A5046077465 @default.
• W2093666912 creator A5046657704 @default.
• W2093666912 creator A5047468243 @default.
• W2093666912 creator A5052642697 @default.
• W2093666912 creator A5057527826 @default.
• W2093666912 creator A5059623423 @default.
• W2093666912 creator A5076822049 @default.
• W2093666912 date "2003-07-23" @default.
• W2093666912 modified "2023-10-17" @default.
• W2093666912 title "Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study" @default.
• W2093666912 cites W1567224726 @default.
• W2093666912 cites W1821554592 @default.
• W2093666912 cites W1867073577 @default.
• W2093666912 cites W1884165293 @default.
• W2093666912 cites W1885881044 @default.
• W2093666912 cites W1888219540 @default.
• W2093666912 cites W1970360147 @default.
• W2093666912 cites W1973170846 @default.
• W2093666912 cites W1987307200 @default.
• W2093666912 cites W2002395765 @default.
• W2093666912 cites W2009570864 @default.
• W2093666912 cites W2012264968 @default.
• W2093666912 cites W2036885415 @default.
• W2093666912 cites W2038962823 @default.
• W2093666912 cites W2039857946 @default.
• W2093666912 cites W2040533210 @default.
• W2093666912 cites W2043738725 @default.
• W2093666912 cites W2077619349 @default.
• W2093666912 cites W2108511043 @default.
• W2093666912 cites W2146353390 @default.
• W2093666912 cites W2159283488 @default.
• W2093666912 cites W2163830215 @default.
• W2093666912 cites W2240465506 @default.
• W2093666912 cites W2327264683 @default.
• W2093666912 cites W2329804409 @default.
• W2093666912 cites W269470825 @default.
• W2093666912 cites W4294233646 @default.
• W2093666912 doi "https://doi.org/10.1046/j.1365-2141.2003.04448.x" @default.
• W2093666912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12877666" @default.
• W2093666912 hasPublicationYear "2003" @default.
• W2093666912 type Work @default.
• W2093666912 sameAs 2093666912 @default.
• W2093666912 citedByCount "314" @default.
• W2093666912 countsByYear W20936669122012 @default.
• W2093666912 countsByYear W20936669122013 @default.
• W2093666912 countsByYear W20936669122014 @default.
• W2093666912 countsByYear W20936669122015 @default.
• W2093666912 countsByYear W20936669122016 @default.
• W2093666912 countsByYear W20936669122017 @default.
• W2093666912 countsByYear W20936669122018 @default.
• W2093666912 countsByYear W20936669122019 @default.
• W2093666912 countsByYear W20936669122020 @default.
• W2093666912 countsByYear W20936669122021 @default.
• W2093666912 countsByYear W20936669122022 @default.
• W2093666912 countsByYear W20936669122023 @default.
• W2093666912 crossrefType "journal-article" @default.
• W2093666912 hasAuthorship W2093666912A5016338515 @default.
• W2093666912 hasAuthorship W2093666912A5017763871 @default.
• W2093666912 hasAuthorship W2093666912A5020989412 @default.
• W2093666912 hasAuthorship W2093666912A5028760009 @default.
• W2093666912 hasAuthorship W2093666912A5032502229 @default.
• W2093666912 hasAuthorship W2093666912A5033539146 @default.
• W2093666912 hasAuthorship W2093666912A5043378112 @default.
• W2093666912 hasAuthorship W2093666912A5046077465 @default.
• W2093666912 hasAuthorship W2093666912A5046657704 @default.
• W2093666912 hasAuthorship W2093666912A5047468243 @default.
• W2093666912 hasAuthorship W2093666912A5052642697 @default.
• W2093666912 hasAuthorship W2093666912A5057527826 @default.
• W2093666912 hasAuthorship W2093666912A5059623423 @default.
• W2093666912 hasAuthorship W2093666912A5076822049 @default.
• W2093666912 hasBestOaLocation W20936669121 @default.
• W2093666912 hasConcept C126322002 @default.
• W2093666912 hasConcept C141071460 @default.
• W2093666912 hasConcept C142724271 @default.
• W2093666912 hasConcept C204787440 @default.
• W2093666912 hasConcept C27081682 @default.
• W2093666912 hasConcept C2776364478 @default.
• W2093666912 hasConcept C2778534260 @default.
• W2093666912 hasConcept C2781404941 @default.
• W2093666912 hasConcept C2908647359 @default.
• W2093666912 hasConcept C71924100 @default.
• W2093666912 hasConcept C90924648 @default.
• W2093666912 hasConcept C99454951 @default.
• W2093666912 hasConceptScore W2093666912C126322002 @default.
• W2093666912 hasConceptScore W2093666912C141071460 @default.
• W2093666912 hasConceptScore W2093666912C142724271 @default.
• W2093666912 hasConceptScore W2093666912C204787440 @default.
• W2093666912 hasConceptScore W2093666912C27081682 @default.
• W2093666912 hasConceptScore W2093666912C2776364478 @default.

• next